Anthem Biosciences IPO Strong Debut on July 21 Shakes Up the Market {update}

What the Company Does

Anthem isn’t your usual pharma player. They operate as a Contract Research, Development, and Manufacturing Organization (CRDMO). Since launching in 2006, they’ve built a global reputation. Their services cover everything from small molecule research to fermentation and biologics. They even handle preclinical safety studies.

The company has two world-class facilities in Bengaluru. Both are certified by regulators like the USFDA, EU, and PMDA Japan, which makes it easier to work with global clients.

You can read our review of a recent IPO in a different sector here: Lamosaic India Limited IPO Review: Share Price, GMP, Dates, and Details

Financials at a Glance

Anthem closed FY25 with ₹1,930 crore in revenue and ₹451 crore in net profit. Their operating margins are solid, around 24%. EPS was ₹8.07 for the year.

Return on Capital Employed (ROCE) stood at 27%, while Return on Equity (ROE) came in at 21%. These figures show strong operational performance and smart capital use. Still, at a P/E of 70, some investors believe the stock isn’t cheap.

IPO Breakdown

• Price Band: ₹540–₹570 per share
• Lot Size: 26 shares
• Minimum Investment: ₹14,820
• IPO Dates: July 14 to July 16
• Type: Entirely an Offer for Sale (OFS) worth ₹3,395 crore

The company didn’t raise any new capital through the IPO. Instead, existing shareholders sold part of their stake.

Subscription Details

• QIBs: 182.65×
• Non-Institutional Investors: 42.36×
• Retail: 5.64×

Total subscription came in at 63.86×, which shows how much confidence investors had going in.

Listing Day Buzz

The stock listed at ₹723, well above the upper band. It even touched ₹746.70 during the day. By closing time, it had settled at ₹731.65 on NSE.

In the grey market, premiums had reached ₹165–₹177 before listing — and the actual debut lived up to the expectations.

If you’re new to IPO investing and want to check listing-day performances or GMP trends, websites like IPOWatch and Chittorgarh are great places to explore.

What Works in Anthem’s Favor

They’ve got a sticky business model. Clients rely on them for end-to-end drug development. That kind of dependency brings long-term revenue. Their presence in biologics and fermentation — two fast-growing segments — also puts them in a sweet spot.

On top of that, regulatory approvals from global authorities give them a strong edge when competing internationally.

What Investors Should Watch

The biggest concern is client concentration. A handful of clients bring in a major chunk of revenue. Losing one could sting. Also, because the IPO was an OFS, the company didn’t get any fresh cash for growth. That might limit expansion in the short term.

The high valuation might also slow down future upside unless earnings keep rising.

Bottom Line

Anthem Biosciences made a statement on Day One. Strong financials, global exposure, and solid demand helped them start with a bang.

Still, investors should keep an eye on how the company performs over the next few quarters. If they continue growing at this pace and manage client relationships well, they could turn into a long-term winner.

For those who missed the IPO, this might be one to watch on dips — especially if the biotech and pharma space continues to attract capital in India.

Disclaimer:
This article is for informational purposes only and should not be considered as investment advice or a recommendation to buy, sell, or hold any shares. Investors are advised to do their own research or consult with a financial advisor before making any investment decisions. Market investments are subject to risks, including the possible loss of principal.

For More IPO Updates:
To stay updated with the latest IPO news, reviews, GMP, and listing analysis, check out our IPO section here.